The Pharma Data

NOVEMBER 8, 2020

PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. This is an important milestone for Sedor Pharmaceuticals and opens a significant global market for the company. About Sedor Pharmaceuticals, LLC. Both products were licensed from Ligand Pharmaceuticals.

FDA Approval 52

FDA Approval FDA Long-Term Care Facilities Treatment 52

The Pharma Data

SEPTEMBER 18, 2020

Vivera Pharmaceutical provides Covid-19 results within 48 hours of initial patient test. Vivera Pharmaceuticals, Inc. The Vivera Pharmaceuticals and OmeCare rRT-PCR specimen collection kits are available for use by medical providers.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

OCTOBER 28, 2020

Lilly has a robust, global supply chain in place to produce bamlanivimab, with five active pharmaceutical ingredients (API) manufacturing sites worldwide. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

JANUARY 24, 2021

Innovation Pharmaceuticals received the greenlight from the FDA to initiate a Phase II trial of Brilacidin in hospitalized COVID-19 patients. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

MAY 4, 2021

A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing. Results from the Phase 2 cohorts of BLAZE-1 were published in the New England Journal of Medicine and The Journal of the American Medical Association.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

DECEMBER 31, 2020

According to the Times , he said that health care facilities are still learning how to store the vaccines at super-low temperatures, and many states are setting aside doses for use at long-term care facilities, an effort that’s expected to take several months. A global scourge. By Thursday, the U.S.

Vaccine 52

Vaccine Long-Term Care Facilities Virus Hospitals 52